Brinker Capital Inc. Purchases 4,924 Shares of Merck & Co., Inc. (NYSE:MRK)

Brinker Capital Inc. raised its stake in Merck & Co., Inc. (NYSE:MRK) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,803 shares of the company’s stock after buying an additional 4,924 shares during the period. Brinker Capital Inc.’s holdings in Merck & Co., Inc. were worth $13,550,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. State Street Corp increased its holdings in Merck & Co., Inc. by 1.0% during the 4th quarter. State Street Corp now owns 116,493,884 shares of the company’s stock worth $10,665,449,000 after acquiring an additional 1,196,724 shares during the period. Janus Henderson Group PLC boosted its position in Merck & Co., Inc. by 16.5% during the 4th quarter. Janus Henderson Group PLC now owns 28,954,215 shares of the company’s stock valued at $2,633,372,000 after buying an additional 4,108,756 shares during the period. UBS Asset Management Americas Inc. boosted its position in Merck & Co., Inc. by 1.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 13,600,258 shares of the company’s stock valued at $1,236,943,000 after buying an additional 191,393 shares during the period. FMR LLC boosted its position in Merck & Co., Inc. by 7.1% during the 4th quarter. FMR LLC now owns 12,486,223 shares of the company’s stock valued at $1,135,622,000 after buying an additional 822,959 shares during the period. Finally, Alliancebernstein L.P. boosted its position in Merck & Co., Inc. by 11.0% during the 4th quarter. Alliancebernstein L.P. now owns 12,132,071 shares of the company’s stock valued at $1,103,412,000 after buying an additional 1,204,495 shares during the period. Hedge funds and other institutional investors own 75.74% of the company’s stock.

In other Merck & Co., Inc. news, EVP Julie L. Gerberding sold 102,073 shares of Merck & Co., Inc. stock in a transaction on Monday, January 13th. The shares were sold at an average price of $89.34, for a total value of $9,119,201.82. Following the completion of the sale, the executive vice president now directly owns 106,099 shares of the company’s stock, valued at $9,478,884.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

NYSE:MRK traded up $2.19 during mid-day trading on Thursday, reaching $70.41. The company’s stock had a trading volume of 341,979 shares, compared to its average volume of 18,445,974. Merck & Co., Inc. has a 1 year low of $65.25 and a 1 year high of $92.64. The stock has a fifty day moving average of $79.60 and a 200-day moving average of $84.79. The firm has a market capitalization of $175.13 billion, a PE ratio of 18.52, a price-to-earnings-growth ratio of 1.76 and a beta of 0.69. The company has a quick ratio of 0.97, a current ratio of 1.24 and a debt-to-equity ratio of 0.87.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Wednesday, February 5th. The company reported $1.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.15 by $0.01. The firm had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Merck & Co., Inc. had a return on equity of 49.41% and a net margin of 21.01%. The company’s revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.04 EPS. On average, analysts expect that Merck & Co., Inc. will post 5.72 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a $0.61 dividend. This represents a $2.44 annualized dividend and a yield of 3.47%. The ex-dividend date is Friday, March 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.01%.

Several research firms have recently commented on MRK. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a research note on Wednesday, February 5th. UBS Group reduced their price target on shares of Merck & Co., Inc. from $99.00 to $96.00 and set a “buy” rating for the company in a research note on Thursday, February 6th. ValuEngine upgraded shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research note on Saturday, February 29th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $92.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, February 6th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $94.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Net Asset Value

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.